Switch to
More onapp

Biocon Ltd

BIOCON
Health CareBiotechnology
MidcapWith a market cap of ₹33,549 cr, stock is ranked 154
Low RiskStock is 1.84x as volatile as Nifty
282.100.90 (+0.32%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CareBiotechnology
MidcapWith a market cap of ₹33,549 cr, stock is ranked 154
Low RiskStock is 1.84x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
51.74
PB RatioPB Ratio
3.54
Dividend YieldDiv. Yield
0.18%
Sector PESector PE
35.92
Sector PBSector PB
4.36
Sector Div YldSctr Div Yld
0.88%

Forecast & RatingsDetailed Forecast 

64%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Biocon Limited is an India-based biopharmaceutical company that focuses to treat diabetes, cancer and autoimmune diseases. The Company is also focused on developing novel therapies for diabetes, oncology and immunology. The Company’s businesses segment includes Generics, Biosimilars, Novel Biologics and Research Services. The Company’s Generic Formulations and API products include Rosuvastatin, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company’s portfolio includes ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.

Brands

Biocon

Biotech company

Investor PresentationView older 

Nov 15, 2022

PDF
View Older Presentations

Brands

Biocon

Biotech company

Financial TrendFinancial statements 

20192020202120225.856.537.418.400.910.750.740.65
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

General updates 
Announced OnNov 24, 2022

Biocon Limited has informed the Exchange about Disclosure pursuant to Regulation 30 | Download

Biocon Limited has informed the Exchange about Disclosure pursuant to Regulation 30 | Download

General updates 
Announced OnNov 24, 2022

Biocon Limited has informed the Exchange about Issue of Commercial Papers of Rs. 2,250 Crores | Download

Biocon Limited has informed the Exchange about Issue of Commercial Papers of Rs. 2,250 Crores | Download

Cash Dividend 
Ex. DateJun 30, 2022

Final • Div/Share: ₹ 0.5

See all events